---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096172"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:45:08.439901+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Korro Bio Q2 net loss $21.8M; cash $187.8M; KRRO-110 FIH filing on track

## Summary
- Net loss of $21.8M for Q2 2024, up from $17.6M in Q2 2023, driven by higher R&D and G&A costs.
- Cash, equivalents & marketable securities total $187.8M as of June 30, 2024; runway into H2 2026.
- Regulatory filing for KRRO-110 first-in-human trial in AATD expected in H2 2024.
- Preclinical data showed >70% M-AAT protein in circulation with ~60% sustained editing efficiency.
- Completed $70M private placement in April 2024 to support pipeline development.

## SEC filing metadata
- accession: 0000950170-24-096172
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/0000950170-24-096172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024096172/krro-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096172
- JSON: https://secwatch.observer/filing/0000950170-24-096172.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.